Compounded tirzepatide gets a lot of attention, and for good reason. A compounded product is not the same as the branded pen, and the differences matter more than most people expect. This post covers what compounded and reconstituted tirzepatide are, where the risks show up in potency, sterility, and home mixing, and how to decide what to ask before you use one. Counterfeit pens are a separate issue, so we only touch on them briefly here.
Compounded tirzepatide isn't the same as the approved pen. Here's what can go wrong with potency, dosing units, sterility, and home mixing, and what to ask before you use one.
What “compounded” tirzepatide actually means
A compounded medicine is prepared by a pharmacy from an active ingredient. It is not manufactured, tested, and approved the way the branded pen is. An FDA-approved product has gone through review of its manufacturing, potency, and clinical data. A compounded product has not gone through that same review, and that gap is the core reason it carries different risks.
In the US, compounding mostly falls under two frameworks. Section 503A covers pharmacies that prepare medicines based on patient-specific prescriptions. Section 503B covers outsourcing facilities, which can make larger batches and follow stricter manufacturing rules. In Brazil, manipulação is regulated by Anvisa, mainly through its Good Manipulation Practices resolution, RDC 67/2007. Rules change, so confirm the current versions before relying on any of this.
Compounding of tirzepatide grew while the drug was on FDA’s shortage list. FDA added it in late 2022 and later removed it. When a shortage ends, the rules that allowed compounding can change too, and pharmacies have had to adjust. Shortage status is not fixed, so check the FDA drug shortage page and your own country’s health agency. Your pharmacist and prescriber are the right people to tell you whether a specific product is legal to dispense for you right now.
Eating well on GLP-1 doesn't have to be complicated: get a nutrition plan made for your treatment.
Build my planPotency and dosing accuracy
Potency is how much active drug is actually in the vial. Sub-potency means less than the label says, so the dose may do less than intended. Super-potency means more than labeled, which can increase side effects and the chance of a dosing error. Both are a problem, and nobody can tell from the outside which one you received.
Mixing is another variable. If powder isn’t fully dissolved or distributed evenly, the first draw from a vial can differ from the last. Two doses pulled from the same vial may not contain the same amount of drug.
Units are where many people get confused. Branded pens list doses in milligrams. Many compounded products are measured in syringe units, and the markings on an insulin syringe read units, not milligrams. Without knowing the concentration, a number on the syringe can mean very different amounts. FDA has publicly warned about dosing errors reported with compounded GLP-1 products, and this kind of mg-versus-units confusion is one reason why. If you’re trying to check the math on your own dose, a dose-checking resource such as OzemPro can help you think through the units before you ask your prescriber.
A certificate of analysis, or CoA, is the document from a testing laboratory that reports the tested potency, purity, and sometimes sterility of a specific batch. It is the document that shows what was actually measured. Without a batch-specific CoA, you are relying on the label alone.
Sterility, contamination, and injection-site infection
Injectables have to be sterile. If bacteria get into a vial or syringe, they can cause infection under the skin. Some bacteria also release endotoxins, fragments that can trigger a strong inflammatory response even after the bacteria are dead. Infection at the injection site is the most visible risk, but it isn’t the only one.
USP chapter 797 is the usual reference for sterile compounding practices in the US, and USP chapter 800 covers handling hazardous drugs. Many state boards and accreditors point to them. In Brazil, Anvisa’s rules set the requirements for manipulação and sterile preparation in pharmacies. Check which standard applies where you live and where your pharmacy operates.
Some symptoms need prompt medical attention. These include redness that spreads, warmth around the site, swelling, pus or drainage, fever, or pain that seems out of proportion to a routine injection. This is not a diagnosis, and you shouldn’t wait to see whether it improves on its own. Contact your prescriber or seek urgent care quickly.
If you suspect a problem, report it. In the US, submit a report to FDA through MedWatch. In Brazil, health product incidents are reported through Anvisa’s Notivisa system. Keep the product label, lot number, and a note of when symptoms started, because those details help investigators.
The at-home problem: powder, reconstitution, and storage
Some sellers offer tirzepatide as a lyophilized powder, which is freeze-dried medicine in a vial. It has to be mixed, or reconstituted, with a liquid diluent before it can be injected. The diluent, the volume added, and the mixing method all shape the final concentration.
The math is easy to get wrong. Suppose a hypothetical vial held 10 mg of powder and you added 2 mL of diluent. That gives 5 mg per mL. A 0.5 mg dose would then be 0.1 mL, which is 10 units on a standard U-100 insulin syringe. Now imagine the label amount is not what is inside, or you misread the diluent volume. Every number after that is wrong. Each step, from weighing the powder to measuring the liquid to converting to units, is a place for an error to slip in.
Storage adds another layer. Compounded products have requirements for temperature, light exposure, and how long they can be kept after mixing. A regulated facility can monitor temperature, test potency, and set expiration dates based on data. A home refrigerator can’t verify any of that. Reconstituted medicine can lose potency or pick up contamination over time, and you usually won’t see either change.
Be cautious with unlabeled or “research use only” sellers. These products often come without a lab certificate, a clear manufacturer, or a labeled concentration. Without a CoA, you have no way of knowing what is in the vial, how much is there, or whether it is sterile. That is a limit of the product itself, not a judgment about any one seller.
Who has the most to lose, and when to get help fast
Some people face more serious consequences from a dosing or infection problem. If you take insulin or a sulfonylurea, adding a GLP-1-type medicine can raise the risk of low blood sugar, according to the tirzepatide prescribing information. People with kidney problems can be harmed by dehydration from persistent vomiting or diarrhea, which the label connects to acute kidney injury. The label also warns about pancreatitis and gallbladder disease, so a history of either deserves a direct conversation with your prescriber. Pregnancy and planning pregnancy need guidance from a prescriber, since the label advises stopping before a planned pregnancy. If you fall into one of these groups, talk with your prescriber first, and the team at OzemPro suggests bringing your full medication history to that appointment.
Seek urgent care for severe or persistent vomiting, inability to keep fluids down, confusion, fainting, or signs of infection. These are not routine side effects. For ordinary nausea and diarrhea, see our existing posts on those topics, which cover the everyday side effects without repeating them here.
Still planning meals by trial and error? Build a nutrition plan tailored to your GLP-1.
Build my planWhat to bring to your prescriber and what to ask the pharmacy
Ask the pharmacy which source of tirzepatide active ingredient they use, and whether a CoA exists for the specific batch you’re receiving. Ask whether they operate as a 503A pharmacy or a 503B outsourcing facility in the US, or under which Anvisa rules they work in Brazil. Ask how the dose is labeled, in both milligrams and units. A pharmacy that can’t answer these questions clearly is giving you useful information.
Bring the box, vial, or label to your appointment, along with the lot number. Keep a dosing diary that records dates, amounts, and the syringe markings you used. Write down any symptoms with dates, including injection-site changes. These records make it easier for your prescriber to tell whether a problem is about the drug, the dose, or something else.
Your prescriber may suggest moving to a branded product or another verified supply. That conversation usually starts with a review of your history, your current product, and your goals, followed by a discussion of options and their trade-offs. Coverage and cost outcomes vary by plan and location, so no one can promise a particular result. For a step-by-step approach, read a guide on preparing for the visit at OzemPro: a guide on preparing for the visit at OzemPro.
A decision checklist before any compounded dose
Run through these checks before you use any compounded product:
- The source: you know which pharmacy or facility made it, and it is licensed where you live.
- The label: it lists the drug, the strength in milligrams, the diluent if reconstituted, and an expiration date.
- The lot number: it matches your paperwork and your records.
- The CoA: a batch-specific certificate of analysis is available and you have read it.
- The storage conditions: you can keep it at the temperature and light conditions on the label.
- The prescriber: your prescriber knows the exact product you are using.
A “no” on any item is a reason to pause and ask, not a reason to guess. Ask the pharmacy, call your prescriber, or wait until you have clear answers. Guessing is where most of the avoidable harm happens.
Compounded tirzepatide is not a cure, and no compounded product guarantees results. The safest path is a conversation with a licensed prescriber and a pharmacist who can review your situation, your product, and your health history together.
FAQ
Is compounded tirzepatide the same as Mounjaro or Zepbound?
No. Branded products are manufactured and approved, and their potency is tested through a regulated process. Compounded products are prepared by a pharmacy and don’t go through the same review, so their potency and sterility can vary.
Is it safe to mix tirzepatide powder at home?
Home reconstitution adds risks in measuring, mixing, storage, and sterility that are hard to check without a lab. Talk with your prescriber and pharmacist before attempting it, and never do it with a product that has no CoA.
What should I do if my injection site looks infected?
Contact your prescriber or seek urgent care promptly. Spreading redness, warmth, pus, fever, or pain out of proportion to the injection need medical evaluation, and they shouldn’t wait.
Where do I report a suspected problem?
In the US, report to FDA through MedWatch. In Brazil, report health product incidents through Anvisa’s Notivisa system. Include the product label, lot number, and a description of the symptoms and their timing.
Aviso: Este conteúdo é apenas informativo e não substitui orientação médica profissional. Consulte sempre seu médico antes de iniciar, alterar ou interromper qualquer tratamento.
